Develops therapies for rare bleeding disorders including Glanzmann thrombasthenia, a genetic platelet disease.
Develops therapies for rare bleeding disorders including Glanzmann thrombasthenia, a genetic platelet disease.
Has no product on sale, so it funds studies from money raised from investors; income would first come from licensing or partnership payments and later from drug sales if a product is approved. Its drugs target conditions with few patients, so one approved product would serve a small group at a high price per patient.
Moat: none (IP / patents). Addresses rare bleeding disorders with limited approved options, but is clinical-stage with small target populations.
Headquarters: Boston, Massachusetts, US · Founded: 2020 · Employees: 72
Size Hemab Therapeutics (COAG) is a United States Health Care company (Biotechnology) with a market value of $1.83B, the 1830th largest of 3,085 United States companies the cockpit tracks. Shares closed at $39.15 on 18 Nov 2026.
Performance Over six months the shares gained 47.9%, against -4.8% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Short interest Short interest is 7.1% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$304,000 | -$248,000 |
| EBITDA | n/a | -$69.8M | -$50.1M |
| Net income | n/a | -$63.9M | -$48.7M |
| Free cash flow | n/a | -$61.5M | -$45.9M |
| Capital expenditure | n/a | $16,000 | $282,000 |
| Total debt | $965,000 | $361M | $206M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Hemab Therapeutics COAG | $1.83B | +48% | n/a | n/a | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 3.9× | -0.5% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COAG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.6% | -6.2% | 2nd highest of 20 |
| 6-month return | +47.9% | -4.8% | 4th highest of 20 |
| Distance from 52-week high | -29.4% | -33.4% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |